In cases in which Oncotype DX test is not available, how do you decide which patients with HR+ and Her2- breast cancer are candidates for adjuvant chemotherapy?  
How would your management differ in pre- and post-menopausal females?


Answer from: Medical Oncologist at Academic Institution